At GeneLancet Biosciences, we’re passionate about unlocking the full potential of therapeutic gene editing. Our advanced technologies in in vivo gene editing, including proprietary ultra-pure scalable guide RNAs (LgRNA) and non-immunogenic STAR editors, are designed to drive scientific breakthroughs from concept to cure. We focus on delivering precise, personalized solutions with real-world impact. (Downloadable: Our Solutions)
New-generation Guide RNA (LgRNA) Platform
- Efficacy: Dual guide RNAs < sgRNA < LgRNA
- LgRNA is highly pure (up to 99% by LC/MS) and free of detectable truncated spacer sequences
- High purity results in very high specificity
- Chemical modifications of LgRNA limit immunogenicity and increase specificities
- LgRNA conjugates enable nucleus uptake and cell-selective delivery
- Robust and scalable in manufacturing
We are committed to advancing scalable precise gene editing through strategic collaborations. Discover more about our LgRNA solutions here.
Non-immunogenic STAR Editor Platform
- Precise CRISPR gene editing by a DNA polymerase
- nCas9/templated DNA repair resulting in minimal DSBs
- RNP conjugates for non-immunogenic targeted delivery
- Ability to insert stop codon anywhere to ensure minimal truncated protein byproducts for anti-cancer and antiviral therapy
- Ability to perform single base corrections, and insert/delete short or long DNAs
- Capability of multiplexing and multiple dosing